A supply deal for NUBEQA was finalized between ORIC Pharmaceuticals and BAYER after talks with the FDA.
2 reports, 1 independent
Updated Sep 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A supply deal for NUBEQA was finalized between ORIC Pharmaceuticals and BAYER after talks with the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.